Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 4,725 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,725 shares of Natera stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total transaction of $1,090,388.25. Following the completion of the transaction, the chief executive officer directly owned 123,156 shares in the company, valued at $28,420,710.12. This represents a 3.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, February 2nd, Steven Leonard Chapman sold 85,299 shares of Natera stock. The stock was sold at an average price of $230.72, for a total value of $19,680,185.28.
• On Wednesday, January 28th, Steven Leonard Chapman sold 3,648 shares of Natera stock. The shares were sold at an average price of $237.66, for a total value of $866,983.68.
• On Tuesday, January 27th, Steven Leonard Chapman sold 2,322 shares of Natera stock. The stock was sold at an average price of $240.53, for a total value of $558,510.66.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The shares were sold at an average price of $229.08, for a total transaction of $881,499.84.
• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The shares were sold at an average price of $238.07, for a total value of $1,047,508.00.

Natera Stock Performance

NTRA stock traded down $22.07 during midday trading on Wednesday, reaching $205.61. The stock had a trading volume of 2,452,176 shares, compared to its average volume of 1,059,726. The firm has a fifty day simple moving average of $234.95 and a two-hundred day simple moving average of $195.74. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36. The stock has a market cap of $28.44 billion, a PE ratio of -89.79 and a beta of 1.64.

Natera (NASDAQ:NTRA) last released its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period last year, the firm earned ($0.26) EPS. The company’s revenue for the quarter was up 34.7% compared to the same quarter last year. On average, sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Thursday, January 22nd. Piper Sandler lifted their target price on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. TD Cowen reiterated a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Morgan Stanley lifted their price objective on shares of Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Finally, Stephens upped their price objective on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $249.20.

Institutional Trading of Natera

Several large investors have recently bought and sold shares of the business. Flagship Harbor Advisors LLC acquired a new position in Natera during the fourth quarter worth $41,000. Hilltop National Bank acquired a new position in Natera during the 2nd quarter worth about $33,000. Horizon Investments LLC purchased a new position in Natera during the 3rd quarter valued at about $32,000. Sound Income Strategies LLC grew its position in Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares in the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new stake in Natera during the fourth quarter worth about $62,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.